Risk Audit · Cached SEC Snapshot

CBIO Risk Audit — Dilution, Cash Runway, and SEC Filings

CRESCENT BIOPHARMA, INC.
TL;DR
Doomsday Clock
61.9mo
Company runs out of cash in 61.9 months
Dilution Risk
0 / 100
Disciplined capital management
C Stockteller Grade Altman Z: 0.74 (Z)
Gravity Playbook · Mathematical Stress Test
AUTH
Dilution Posture
The company has an active S-3 shelf registration, authorizing future equity offerings. However, there is no active dilution program currently in place.
BURN
Cash Runway
Current mechanics indicate the company's cash runway is mathematically depleted in approximately 61.9 months.
COMPLIANCE
Nasdaq Compliance
Nasdaq requires a $1.00 minimum bid. Historical precedent for companies with this profile involves structural actions such as reverse splits to maintain listing compliance.
Mechanical analysis only. Not financial advice. Statements describe mathematical conditions and historical precedent, not predictions or recommendations for this security.
→ Run the Full Risk Sentinel Scan for CBIO Compare CBIO vs AAPL Risk → Learn how the Risk Radar works →
Contagion Watch
Other tickers the Risk Sentinel just flagged
Is your portfolio hiding a toxic S-3?
Run any ticker through the same Risk Sentinel scan — free.
Educational analysis only. Not financial advice. The Risk Audit is a quantitative framework derived from publicly available SEC filings and may contain inaccuracies. AI systems are fallible. Always verify against the source filings on SEC EDGAR and consult a licensed advisor before making investment decisions.